Urogen Pharma Ltd.(URGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

URGN Urogen Pharma Ltd.

Trading 03-28 13:24:19 EDT

11.25

-0.20

-1.75%

High11.55	Low11.18	Vol49.21K
Open11.47	D1 Closing11.45	Amplitude3.28%
Mkt Cap518.56M	Tradable Cap416.17M	Total Shares46.09M
T/O556.49K	T/O Rate0.13%	Tradable Shares36.99M
P/B-58.91	ROE-1481.26%	EPS-2.96
52wk High20.70	52wk Low9.03	P/E-3.80
Dividend0.00	Div.Yield0.00	ROA-25.78%

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"URGN","market":"US","secType":"STK","nameCN":"Urogen Pharma Ltd.","latestPrice":11.25,"timestamp":1743182637046,"preClose":11.45,"halted":0,"volume":49209,"delay":0,"floatShares":36992700,"shares":46094399,"eps":-2.95904,"marketStatus":"Trading","change":-0.2,"latestTime":"03-28 13:24:19 EDT","open":11.47,"high":11.553,"low":11.1776,"amount":556493.8534380001,"amplitude":0.032786,"askPrice":11.33,"askSize":231,"bidPrice":11.23,"bidSize":11,"shortable":3,"etf":0,"ttmEps":-2.95904,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1743192000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1493870400000,"exchange":"NASDAQ","adjPreClose":11.45,"preHourTrading":{"tag":"盘前","latestPrice":11.34,"preClose":11.45,"latestTime":"09:28 EDT","volume":100,"amount":1134,"timestamp":1743168537092},"postHourTrading":{"tag":"盘后","latestPrice":11.45,"preClose":11.45,"latestTime":"16:36 EDT","volume":170208,"amount":1948881.6,"timestamp":1743107808688},"volumeRatio":0.164825,"impliedVol":0.7986,"impliedVolPercentile":0.508},"requestUrl":"/m/hq/s/URGN","defaultTab":"news","newsList":[{"id":"2518196467","title":"UroGen Pharma price target lowered to $55 from $64 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2518196467","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518196467?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 18:15","pubTimestamp":1741688118,"startTime":"0","endTime":"0","summary":"H.C. Wainwright lowered the firm’s price target on UroGen Pharma (URGN) to $55 from $64 and keeps a Buy rating on the shares. The company reported ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/urogen-pharma-price-target-lowered-to-55-from-64-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/urogen-pharma-price-target-lowered-to-55-from-64-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["URGN","BK4139"],"gpt_icon":0},{"id":"2518077192","title":"Analysts Offer Insights on Healthcare Companies: Inozyme Pharma (INZY) and Urogen Pharma (URGN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2518077192","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518077192?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 03:50","pubTimestamp":1741636209,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Inozyme Pharma (INZY – Research Report) and Urogen P...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-inozyme-pharma-inzy-and-urogen-pharma-urgn?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-inozyme-pharma-inzy-and-urogen-pharma-urgn?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","BK4139","INZY","URGN","BK4137"],"gpt_icon":0},{"id":"2518274835","title":"Urogen Pharma Ltd reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2518274835","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518274835?lang=en_us&edition=full_marsco","pubTime":"2025-03-10 23:38","pubTimestamp":1741621136,"startTime":"0","endTime":"0","summary":"Urogen Pharma Ltd reports results for the quarter ended December 31 - Earnings SummaryUrogen Pharma Ltd URGN.OQ reported a quarterly adjusted loss of 80 cents per share for the quarter ended December ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nL8N3PT1H6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["URGN"],"gpt_icon":0},{"id":"2518727950","title":"Urogen Pharma reports wider-than-expected fourth-quarter loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2518727950","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518727950?lang=en_us&edition=full_marsco","pubTime":"2025-03-10 23:10","pubTimestamp":1741619446,"startTime":"0","endTime":"0","summary":"March 10 (Reuters) - Urogen Pharma Ltd ::*UROGEN PHARMA Q4 OPERATING EXPENSES USD 49.752 MILLION*UROGEN PHARMA Q4 BASIC EPS USD -0.8*UROGEN PHARMA Q4 OPERATING INCOME USD -27.658 MILLION VERSUS. IBES ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nRSDbxwzNZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","URGN"],"gpt_icon":0},{"id":"2518275948","title":"UroGen Pharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2518275948","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518275948?lang=en_us&edition=full_marsco","pubTime":"2025-03-10 22:46","pubTimestamp":1741617960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/URGN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 10, 2025 10:46 ET (14:46 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["URGN"],"gpt_icon":0},{"id":"2518278206","title":"Urogen Pharma (URGN) Reports Q4 Loss, Lags Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2518278206","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518278206?lang=en_us&edition=full_marsco","pubTime":"2025-03-10 21:10","pubTimestamp":1741612220,"startTime":"0","endTime":"0","summary":"Urogen Pharma  came out with a quarterly loss of $0.80 per share versus the Zacks Consensus Estimate of a loss of $0.74. This compares to loss of $0.72 per share a year ago. These figures are adjusted for non-recurring items.Urogen Pharma , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $24.57 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 6.08%. This compares to year-ago revenues of $23.53 million. The company has topped consensus revenue estimates just once over the last four quarters.Urogen Pharma shares have lost about 7.8% since the beginning of the year versus the S&P 500's decline of -1.9%.While Urogen Pharma has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/urogen-pharma-urgn-reports-q4-131020796.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["URGN"],"gpt_icon":0},{"id":"2518622840","title":"UroGen Pharma Q4 2024 GAAP EPS $(0.80) Misses $(0.68) Estimate, Sales $24.57M Miss $25.63M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2518622840","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518622840?lang=en_us&edition=full_marsco","pubTime":"2025-03-10 20:01","pubTimestamp":1741608091,"startTime":"0","endTime":"0","summary":"UroGen Pharma (NASDAQ:URGN) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $(0.68) by 17.65 percent. This is a 11.11 percent decrease over losses of $(0.72) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44216741/urogen-pharma-q4-2024-gaap-eps-0-80-misses-0-68-estimate-sales-24-57m-miss-25-63m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"UroGen Pharma Q4 2024 GAAP EPS $(0.80) Misses $(0.68) Estimate, Sales $24.57M Miss $25.63M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["URGN"],"gpt_icon":0},{"id":"2518225832","title":"UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102","url":"https://stock-news.laohu8.com/highlight/detail?id=2518225832","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518225832?lang=en_us&edition=full_marsco","pubTime":"2025-03-10 20:00","pubTimestamp":1741608000,"startTime":"0","endTime":"0","summary":"UGN-102 Pivotal ENVISION trial demonstrated an 18-month DOR of 80.6% , by Kaplan-Meier estimate, for patients who achieved a complete response  at three months after the first instillation of UGN-102. New drug application  for UGN-102 under review by the FDA; Prescription Drug User Fee Act  target action date set for June 13, 2025. Acquired a next-generation investigational oncolytic virus  and announced multiple strategic research collaborations in support of long-term growth strategy. JELMYTO achieved net product revenue of $90.4 million in 2024, compared with $82.7 million in 2023, driven by underlying demand revenue growth of 12% for 2024 and 15% for Q4 2024. $241.7 million in cash, cash equivalents and marketable securities as of December 31, 2024. Conference call and webcast to be held today at 10:00 AM ET. PRINCETON, N.J., March 10, 2025----UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/urogen-pharma-reports-fourth-quarter-120000884.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4161","URGN","BK4139","CR"],"gpt_icon":0},{"id":"2517914455","title":"Exploring High Growth Tech Stocks in the US Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2517914455","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517914455?lang=en_us&edition=full_marsco","pubTime":"2025-03-08 01:08","pubTimestamp":1741367302,"startTime":"0","endTime":"0","summary":"Over the last 7 days, the United States market has dropped 2.7%, yet in the longer term, it has risen by 11% over the past year with earnings forecasted to grow by 14% annually. In this context of fluctuating short-term performance and promising long-term growth prospects, identifying high growth tech stocks involves evaluating companies that demonstrate strong innovation potential and resilience in adapting to changing market conditions.Top 10 High Growth Tech Companies In The United States. Click here to see the full list of 235 stocks from our US High Growth Tech and AI Stocks screener.Examine ARS Pharmaceuticals' past performance report to understand how it has performed in the past.Overview: UroGen Pharma Ltd. is a biotechnology company focused on developing and commercializing treatments for urothelial and specialty cancers, with a market ca","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exploring-high-growth-tech-stocks-170822327.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PEGA","URGN","SPRY","BK4139"],"gpt_icon":0},{"id":"2517438613","title":"UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517438613","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517438613?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 21:00","pubTimestamp":1741352400,"startTime":"0","endTime":"0","summary":"PRINCETON, N.J., March 07, 2025----UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units  to 7 new employees in connection with their employment with UroGen. These new team members will support the ongoing commercialization of Jelmyto  for pyelocalyceal solution, UroGen’s first approved product, and the continued development of the Company’s pipeline.Up to 18,500 ordinary shares of UroGen are issuable upon the vesting and settlement of the RSUs. The RSUs will vest equally over three years, with one-third of the underlying shares vesting each year on the anniversary of the vesting date, subject in each case to the employee’s continued service relationship with UroGen.The RSUs are subject to the terms and conditions of UroGen’s 2019 Inducement Plan and RSU grant notice and agreement thereunder. The RSUs were granted as an inducemen","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/urogen-pharma-announces-inducement-grants-130000480.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","USJW.SI","IE00BGHQF748.EUR","MNQmain","PSQ","URGN","BK4585","BK4112","NQmain","LU2210150020.SGD","QID","USAW.SI","SQQQ","BK4588","TQQQ","LU2210149790.SGD","TSYW.SI",".IXIC","IE00BKPKM429.USD","IE00B3QW5Z07.USD","QLD","NDAQ","NVIW.SI","LU2095319765.USD","IE00B64PRP62.GBP"],"gpt_icon":1},{"id":"2517859394","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2517859394","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517859394?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 19:00","pubTimestamp":1741345200,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Algonquin Pwr & Utl                              4Q       .09       BMO. ·Asana Inc. Class A                              4Q      (.01)  4:05 PM. ·Auna S.A. Class A                               4Q       .15       AMC. ·Vail Resorts Inc.                                2Q      6.29   4:05 PM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FERG","DRUG","LRMR","CVGW","CINT","ACET","SSP","FTCI","WEST","NKTR","CDTX","MGTX","CIEN","HLLY","NOA","DRRX","SFIX","ADBE","GECC","ORCL","TBRG","AUNA","ARCO","ZVRA","BBCP","LE","DKS","AMRN","EWCZ","AEO","CHRS","BNTX","ATLC","BWMN","LEN.B","LMB","AURA","CING","URGN","EVEX","ASRT","MOMO","VTS","BDTX","BTMD","BW","KRMD","KALV","MYPS"],"gpt_icon":1},{"id":"2514046508","title":"Press Release: UroGen Pharma to Report Fourth Quarter and Full-Year 2024 Financial Results on Monday, March 10, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2514046508","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514046508?lang=en_us&edition=full_marsco","pubTime":"2025-02-27 21:05","pubTimestamp":1740661500,"startTime":"0","endTime":"0","summary":"Conference Call and Webcast Scheduled for Monday, March 10, 2025, at 10:00 AM ET. UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report fourth quarter and full-year 2024 financial results on Monday, March 10, 2025, prior to the open of the stock market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time.UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therap","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","URGN","BK4022","R","BK4139"],"gpt_icon":0},{"id":"2514509996","title":"UroGen Pharma Price Target Maintained With a $64.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2514509996","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514509996?lang=en_us&edition=full_marsco","pubTime":"2025-02-25 20:42","pubTimestamp":1740487320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/URGN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 25, 2025 07:42 ET (12:42 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["URGN"],"gpt_icon":0},{"id":"2512648727","title":"UroGen Pharma Coverage Assumed by Ladenburg Thalmann at Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2512648727","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512648727?lang=en_us&edition=full_marsco","pubTime":"2025-02-20 01:27","pubTimestamp":1739986020,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/URGN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 19, 2025 12:27 ET (17:27 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["URGN","BK4139"],"gpt_icon":0},{"id":"2512515105","title":"UroGen Pharma transferred with Buy rating at Ladenburg","url":"https://stock-news.laohu8.com/highlight/detail?id=2512515105","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512515105?lang=en_us&edition=full_marsco","pubTime":"2025-02-19 19:56","pubTimestamp":1739966190,"startTime":"0","endTime":"0","summary":"Ladenburg kept a Buy rating on UroGen Pharma (URGN) with a $31 price target following a transfer of coverage. The firm sees a “de-risked path” to a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/urogen-pharma-transferred-with-buy-rating-at-ladenburg?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/urogen-pharma-transferred-with-buy-rating-at-ladenburg?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","URGN"],"gpt_icon":0},{"id":"2512443151","title":"UroGen Pharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2512443151","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512443151?lang=en_us&edition=full_marsco","pubTime":"2025-02-18 20:25","pubTimestamp":1739881500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/URGN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 18, 2025 07:25 ET (12:25 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["URGN"],"gpt_icon":0},{"id":"2511861182","title":"UroGen announces results from subgroup analyses of ENVISION trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2511861182","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511861182?lang=en_us&edition=full_marsco","pubTime":"2025-02-15 03:35","pubTimestamp":1739561711,"startTime":"0","endTime":"0","summary":"UroGen Pharma (URGN) announced results from the subgroup analyses of the pivotal ENVISION study evaluating the impact of tumor burden and focality ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/urogen-announces-results-from-subgroup-analyses-of-envision-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/urogen-announces-results-from-subgroup-analyses-of-envision-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","URGN"],"gpt_icon":0},{"id":"2510306474","title":"UroGen Pharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2510306474","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510306474?lang=en_us&edition=full_marsco","pubTime":"2025-02-12 23:25","pubTimestamp":1739373900,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/URGN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 12, 2025 10:25 ET (15:25 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["URGN"],"gpt_icon":0},{"id":"2510637949","title":"UroGen Pharma announces results from long-term Jelmyto follow-up study","url":"https://stock-news.laohu8.com/highlight/detail?id=2510637949","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510637949?lang=en_us&edition=full_marsco","pubTime":"2025-02-12 21:05","pubTimestamp":1739365524,"startTime":"0","endTime":"0","summary":"UroGen Pharma (URGN) highlighted results from a long-term follow-up study with Jelmyto for pyelocalyceal solution, which is FDA approved for the tr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/urogen-pharma-announces-results-from-long-term-jelmyto-follow-up-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/urogen-pharma-announces-results-from-long-term-jelmyto-follow-up-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["URGN","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.urogen.com","stockEarnings":[{"period":"1week","weight":-0.0474},{"period":"1month","weight":0.204},{"period":"3month","weight":0.0641},{"period":"6month","weight":-0.1124},{"period":"1year","weight":-0.2346},{"period":"ytd","weight":0.0751}],"compareEarnings":[{"period":"1week","weight":0.0028},{"period":"1month","weight":-0.0457},{"period":"3month","weight":-0.0469},{"period":"6month","weight":-0.0077},{"period":"1year","weight":0.0839},{"period":"ytd","weight":-0.0324}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.05646},{"month":2,"riseRate":0.25,"avgChangeRate":-0.051697},{"month":3,"riseRate":0.375,"avgChangeRate":-0.005246},{"month":4,"riseRate":0.428571,"avgChangeRate":0.047176},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.063806},{"month":6,"riseRate":0.75,"avgChangeRate":0.090095},{"month":7,"riseRate":0.375,"avgChangeRate":0.094228},{"month":8,"riseRate":0.5,"avgChangeRate":0.031703},{"month":9,"riseRate":0.25,"avgChangeRate":-0.055568},{"month":10,"riseRate":0.5,"avgChangeRate":0.022641},{"month":11,"riseRate":0.625,"avgChangeRate":0.057405},{"month":12,"riseRate":0.375,"avgChangeRate":-0.059961}],"exchange":"NASDAQ","name":"Urogen Pharma Ltd.","nameEN":"Urogen Pharma Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Urogen Pharma Ltd.(URGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Urogen Pharma Ltd.(URGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Urogen Pharma Ltd.,URGN,Urogen Pharma Ltd.股票,Urogen Pharma Ltd.股票老虎,Urogen Pharma Ltd.股票老虎国际,Urogen Pharma Ltd.行情,Urogen Pharma Ltd.股票行情,Urogen Pharma Ltd.股价,Urogen Pharma Ltd.股市,Urogen Pharma Ltd.股票价格,Urogen Pharma Ltd.股票交易,Urogen Pharma Ltd.股票购买,Urogen Pharma Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Urogen Pharma Ltd.(URGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Urogen Pharma Ltd.(URGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction